Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPI-005
- Development stage
- Preclinical
- Lead developer
- Curadel
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
CPI-005 is a next-generation MRI contrast agent currently in preclinical development by Curadel. It is designed as a zwitterionic chelator, a structural approach intended to optimize the pharmacokinetic and safety profile of contrast media. Zwitterionic molecules carry both positive and negative charges but are net neutral, which can lead to reduced non-specific binding to proteins and tissues, faster renal clearance, and a lower risk of long-term metal retention compared to traditional gadolinium-based contrast agents (GBCAs). The agent is being developed for general MRI contrast imaging applications, with proof-of-concept studies underway.
Beyond the preview
Go deeper on CPI-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPI-005.